Monaco Asset Management SAM Has $5.79 Million Stock Position in QuidelOrtho Corporation $QDEL

Posted by on Jun 1st, 2026

Monaco Asset Management SAM lifted its position in shares of QuidelOrtho Corporation (NASDAQ:QDEL – Free Report) by 131.0% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 202,595 shares of the company’s stock after buying an additional 114,895 shares during the quarter. QuidelOrtho comprises 1.0% of Monaco Asset Management SAM’s holdings, making the stock its 23rd biggest position. Monaco Asset Management SAM owned 0.30% of QuidelOrtho worth $5,786,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Invesco Ltd. raised its stake in QuidelOrtho by 87.0% in the third quarter. Invesco Ltd. now owns 2,906,763 shares of the company’s stock valued at $85,604,000 after purchasing an additional 1,352,503 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in QuidelOrtho by 14.0% in the third quarter. Dimensional Fund Advisors LP now owns 2,859,455 shares of the company’s stock valued at $84,208,000 after purchasing an additional 350,636 shares in the last quarter. State Street Corp raised its stake in QuidelOrtho by 23.3% in the second quarter. State Street Corp now owns 2,700,940 shares of the company’s stock valued at $77,841,000 after purchasing an additional 510,291 shares in the last quarter. Newtyn Management LLC raised its stake in QuidelOrtho by 58.3% in the third quarter. Newtyn Management LLC now owns 2,700,000 shares of the company’s stock valued at $79,515,000 after purchasing an additional 994,332 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in QuidelOrtho by 10.4% in the third quarter. American Century Companies Inc. now owns 2,115,557 shares of the company’s stock valued at $62,303,000 after purchasing an additional 199,909 shares in the last quarter. Institutional investors and hedge funds own 99.00% of the company’s stock.

QuidelOrtho Stock Performance

NASDAQ:QDEL opened at $13.02 on Monday. The firm’s fifty day moving average is $13.41 and its 200-day moving average is $21.84. The company has a debt-to-equity ratio of 1.33, a quick ratio of 0.80 and a current ratio of 1.43. QuidelOrtho Corporation has a 52 week low of $9.92 and a 52 week high of $35.58. The firm has a market cap of $887.83 million, a P/E ratio of -0.73 and a beta of 0.77.

QuidelOrtho (NASDAQ:QDEL – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. The firm had revenue of $619.80 million during the quarter, compared to the consensus estimate of $665.23 million. During the same period in the prior year, the company posted $0.74 earnings per share. The company’s revenue for the quarter was down 10.5% compared to the same quarter last year. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. Equities analysts expect that QuidelOrtho Corporation will post 1.83 earnings per share for the current year.

Analysts Set New Price Targets

QDEL has been the topic of a number of recent analyst reports. Jefferies Financial Group cut QuidelOrtho from a “buy” rating to a “hold” rating and decreased their target price for the company from $35.00 to $12.50 in a research report on Thursday, May 7th. Wall Street Zen cut QuidelOrtho from a “buy” rating to a “hold” rating in a research report on Sunday, April 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of QuidelOrtho in a research report on Tuesday, April 21st. Citigroup decreased their target price on QuidelOrtho from $30.00 to $13.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Finally, Zacks Research cut QuidelOrtho from a “hold” rating to a “strong sell” rating in a research report on Tuesday, February 17th. Three analysts have rated the stock with a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Reduce” and an average target price of $14.88.

View Our Latest Stock Report on QDEL

QuidelOrtho Profile

(Free Report)

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.

Read More

Institutional Ownership by Quarter for QuidelOrtho (NASDAQ:QDEL)

Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with MarketBeat.com's FREE daily email newsletter.